Tianjin Med J ›› 2017, Vol. 45 ›› Issue (12): 1333-1336.doi: 10.11958/20170724

Previous Articles     Next Articles

Research progress of IL-8 in lung cancer

MIAO Ya-jing1, JIN Fang2, XU Peng-yu2, QIU Xiao-fei2△   

  1. 1 Research Center for Basic Medical Science, 2 Department of Pathology, Tianjin Medical University, Tianjin 300070, China △Corresponding Author E-mail: qiouxf@tmu.edu.cn
  • Received:2017-06-22 Revised:2017-09-22 Published:2017-12-15 Online:2017-12-15

Abstract: Lung cancer is the leading cause of cancer-related deaths worldwide. Acquired drug resistance and metastasis are the main causes of treatment failure in lung cancer. Tumor microenvironment is a complex network for the survival and progression of tumor cells, in which inflammatory factors play a critical role in drug resistance and metastasis. Interleukin (IL)-8 is one of critical pro-inflammatory cytokines responsible for cell proliferation, invasion and metastasis, drug resistance and early recurrence in lung cancer. A serum based approach is advantageous for providing a real-time detection and evaluation of disease status in patients. In this review, we summarize the recent advances of IL-8 in predicting prognosis and radiation-induced lung toxicity (RILT), as well as increasing resistance and stem-like characteristics of lung cancer.

Key words: lung neoplasms, interleukin-8, cancer stem cells, prognosis, review